Mallinckrodt names new directors
5 February 2024 -

Mallinckrodt plc, an Irish-American global specialty pharmaceutical company, announced on Friday that it has named Paul Bisaro, Katina Dorton, Abbas Hussain and Wesley Wheeler as its new directors, effective immediately.

Bisaro has over three decades of leadership experience at generic and branded pharmaceutical companies. He has worked as Mallinckrodt's board chair, president, CEO and a director of Impax Laboratories, executive chairman of Amneal Pharmaceuticals, executive chairman of Allergan, president and CEO of Actavis (formerly Watson Pharmaceuticals), and president, chief operating officer and a director of Barr Pharmaceuticals. He works on the boards of Zoetis and Myriad Genetics and earlier worked on the boards of TherapeuticsMD and Zimmer Biomet.

Katina Dorton has over 20 years of finance and healthcare experience across fundraising, mergers and acquisitions, and business development, most recently serving as chief financial officer of NodThera. She has worked as CFO of Repare Therapeutics, AVROBIO and Inmatics and, earlier in her career, she served as a healthcare investment banker at Morgan Stanley and Needham. She works on the boards of Fulcrum Therapeutics and TScan Therapeutics and earlier served on the boards of Pandion Therapeutics and US Ecology, among others.

Hussain has over 30 years of leadership and operating experience in healthcare, most recently serving as Vifor CEO. He earlier worked as GlaxoSmithKline's global president, Pharmaceuticals & Vaccines, and in various leadership roles at Eli Lilly and Company. He also has worked on the boards of Teva Pharmaceuticals, Aspen Pharmacare, Vifor, ViiV Healthcare and Cochlear, among others.

Wheeler has over 40 years of diversified leadership experience in healthcare, including business turnarounds and transformations, manufacturing, marketing, engineering, R&D and supply chain. Presently, he is a Pharmaceutical Services Consultant to KKR. He has earlier worked as president of UPS Healthcare and its subsidiary Marken LLP, CEO, president and a director of Patheon (now a Thermo Fisher Scientific company), and president, R&D and Global Manufacturing at Valeant Pharmaceuticals. He has served in various leadership roles at GlaxoSmithKline and ExxonMobil in engineering, marketing and manufacturing.